+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID07093606

Study of Liver Dysfunction Caused by Eltrombopag in Adults with Immune Thrombocytopenia

Led by Sohag University · Updated on 2025-07-30

100

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the occurrence and severity of liver dysfunction in patients with immune thrombocytopenia ITP who receive the drug eltrombopag as part of their treatment. This study aims to better understand potential liver-related side effects in this patient group. The trial is interventional and sponsored by Sohag University. Participants with ITP will receive eltrombopag tablets. Throughout the study, liver function tests will be performed to monitor for any liver disorders. The primary outcome is to assess liver dysfunction incidence and severity between 3 to 6 months after starting eltrombopag. During the study, participants will have regular liver function tests to evaluate their liver health. Researchers will measure the liver function changes and document any liver-related adverse effects. The total participation period includes the treatment and follow-up for 3 to 6 months after starting eltrombopag, ensuring careful monitoring of liver status during this time.

CONDITIONS

Brief Title

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

Research Team

P

Peter A Alfy, Resident

U

Usama M Abdelaal, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here